Analysts: Cephalon lawsuit won't result in Provigil competition

02/14/2008 | Houston Chronicle (tiered subscription model)

Analysts have dismissed concerns that the new Federal Trade Commission lawsuit against drugmaker Cephalon will lead to generic competition to Provigil, the company's sleep disorder treatment. The company has a good chance of beating the FTC's allegation that it engaged in pay-for-delay deals with generic-drug makers, the experts said, and a final ruling isn't expected before 2011.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT